-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Maintains Overweight on Definium Therapeutics, Lowers Price Target to $48

Benzinga·05/08/2026 15:05:22
Listen to the news
Piper Sandler analyst David Amsellem maintains Definium Therapeutics (NASDAQ:DFTX) with a Overweight and lowers the price target from $49 to $48.